Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

Prospective, Longitudinal, Multinational Registry of Patients With Newly Diagnosed Peripheral T-Cell Lymphoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01110733

Acronym

COMPLETE

Enrollment

3000

Registered

2010-04-27

Start date

2010-02-28

Completion date

2019-12-31

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral T-cell Lymphoma

Keywords

Non-Hodgkins Lymphoma, Non-Hodgkin's Lymphoma, Lymphoma

Brief summary

Prospective, longitudinal, multinational, observational study that will collect data on how patients with peripheral T-cell lymphoma (PTCL) are treated in academic and community practices.

Detailed description

The COMPLETE registry is a prospective, longitudinal, multinational, observational study that will collect data on how patients with peripheral T-cell lymphoma (PTCL) are treated in academic and community practices. The registry will enroll newly-diagnosed patients with PTCL treated with a variety of regimens. The COMPLETE registry is designed to better understand PTCL patient characteristics, treatments, and outcomes to help design and understand future clinical trials.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patient is newly diagnosed with Peripheral T-cell Lymphoma (PTCL): * Aggressive natural killer (NK)-cell leukemia * Adult T-cell lymphoma/leukemia (human T-cell leukemia virus \[HTLV\] 1+) * Angioimmunoblastic T-cell lymphoma * Anaplastic large cell lymphoma (ALCL), primary systemic type (ALK+, ALK-) * PTCL, not otherwise specified (NOS) * T/NK-cell lymphoma, nasal type * Enteropathy-type intestinal lymphoma * Hepatosplenic T-cell lymphoma * Subcutaneous panniculitis T-cell lymphoma * Transformed mycosis fungoides (at diagnosis of transformation) * T-cell prolymphocytic leukemia (T-PLL) * Cutaneous gamma/delta (γ/δ) T-cell lymphoma * Cutaneous aggressive CD8+ T-cell lymphoma * Hematodermic neoplasms (blastic plasmacytoid dendritic cell neoplasm) * Systemic Epstein Barr Virus (EBV)+ T-cell lymphomas (T-cell lymphoproliferative disorders of childhood) * Other T-Cell lymphomas that are not listed in the

Exclusion criteria

* Patient gives written informed consent

Countries

United States

Outcome results